Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Incyte begins Phase II REACH-1 trial of ruxolitinib combined with corticosteroids to treat GVHD

Go Top